RU2697412C2 - Экспресс-тест на основе ПЦР, позволяющий предсказывать чувствительность опухоли головного мозга конкретного пациента к онколитическим вирусам - Google Patents

Экспресс-тест на основе ПЦР, позволяющий предсказывать чувствительность опухоли головного мозга конкретного пациента к онколитическим вирусам Download PDF

Info

Publication number
RU2697412C2
RU2697412C2 RU2016150452A RU2016150452A RU2697412C2 RU 2697412 C2 RU2697412 C2 RU 2697412C2 RU 2016150452 A RU2016150452 A RU 2016150452A RU 2016150452 A RU2016150452 A RU 2016150452A RU 2697412 C2 RU2697412 C2 RU 2697412C2
Authority
RU
Russia
Prior art keywords
pcr
sensitivity
viruses
oncolytic
oncolytic viruses
Prior art date
Application number
RU2016150452A
Other languages
English (en)
Russian (ru)
Other versions
RU2016150452A3 (de
RU2016150452A (ru
Inventor
Анастасия Валерьевна Липатова
Анна Викторовна Кудрявцева
Дмитрий Владимирович Кочетков
Андрей Олегович Желтухин
Анастасия Олеговна Сосновцева
Пётр Михайлович Чумаков
Original Assignee
Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им. В.А. Энгельгардта Российской академии наук
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им. В.А. Энгельгардта Российской академии наук filed Critical Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им. В.А. Энгельгардта Российской академии наук
Priority to RU2016150452A priority Critical patent/RU2697412C2/ru
Publication of RU2016150452A publication Critical patent/RU2016150452A/ru
Publication of RU2016150452A3 publication Critical patent/RU2016150452A3/ru
Application granted granted Critical
Publication of RU2697412C2 publication Critical patent/RU2697412C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2016150452A 2016-12-21 2016-12-21 Экспресс-тест на основе ПЦР, позволяющий предсказывать чувствительность опухоли головного мозга конкретного пациента к онколитическим вирусам RU2697412C2 (ru)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2016150452A RU2697412C2 (ru) 2016-12-21 2016-12-21 Экспресс-тест на основе ПЦР, позволяющий предсказывать чувствительность опухоли головного мозга конкретного пациента к онколитическим вирусам

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016150452A RU2697412C2 (ru) 2016-12-21 2016-12-21 Экспресс-тест на основе ПЦР, позволяющий предсказывать чувствительность опухоли головного мозга конкретного пациента к онколитическим вирусам

Publications (3)

Publication Number Publication Date
RU2016150452A RU2016150452A (ru) 2018-06-22
RU2016150452A3 RU2016150452A3 (de) 2018-12-11
RU2697412C2 true RU2697412C2 (ru) 2019-08-14

Family

ID=62713247

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016150452A RU2697412C2 (ru) 2016-12-21 2016-12-21 Экспресс-тест на основе ПЦР, позволяющий предсказывать чувствительность опухоли головного мозга конкретного пациента к онколитическим вирусам

Country Status (1)

Country Link
RU (1) RU2697412C2 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001861B1 (ru) * 1996-07-12 2001-10-22 Фёрст Опинион Корпорейшн Автоматизированная система медицинской диагностики и советов по лечению, включая сетевой доступ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001861B1 (ru) * 1996-07-12 2001-10-22 Фёрст Опинион Корпорейшн Автоматизированная система медицинской диагностики и советов по лечению, включая сетевой доступ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OTTOLINO-PERRY K. et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010 Feb; 18(2): 251-63. *
OTTOLINO-PERRY K. et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010 Feb; 18(2): 251-63. STOJDL D.F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolyticvirus. Nat Med. 2000 Jul; 6(7): 821-5. *
STOJDL D.F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolyticvirus. Nat Med. 2000 Jul; 6(7): 821-5. *

Also Published As

Publication number Publication date
RU2016150452A3 (de) 2018-12-11
RU2016150452A (ru) 2018-06-22

Similar Documents

Publication Publication Date Title
Wang et al. Development of a real-time loop-mediated isothermal amplification (LAMP) assay and visual LAMP assay for detection of African swine fever virus (ASFV)
Xu et al. Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: discovery of a new bunyavirus
Luo et al. Development of an updated PCR assay for detection of African swine fever virus
Leung et al. Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion
Parker et al. Application of next generation sequencing for the detection of human viral pathogens in clinical specimens
WO2018035860A1 (zh) 同时检测及定量分析四种血源性病毒的多重Taqman探针qPCR的试剂盒及方法
Lewandowska et al. Unbiased metagenomic sequencing complements specific routine diagnostic methods and increases chances to detect rare viral strains
RU2731390C1 (ru) Тест-система и способ для выявления РНК коронавируса SARS-COV-2, вируса-возбудителя коронавирусного заболевания 2019 COVID-19, методом полимеразной цепной реакции в режиме реального времени (Варианты)
Wang COVID− 19, anti-NMDA receptor encephalitis and microRNA
Mahony et al. Development of a novel bead-based multiplex PCR assay for combined subtyping and oseltamivir resistance genotyping (H275Y) of seasonal and pandemic H1N1 influenza A viruses
Dedkov et al. Retrospective diagnosis of two rabies cases in humans by high throughput sequencing
Viedma et al. Optimization of qRT-PCR assay for zika virus detection in human serum and urine
Yang et al. Development of a quadruple qRT-PCR assay for simultaneous identification of highly and low pathogenic H7N9 avian influenza viruses and characterization against oseltamivir resistance
Pripuzova et al. Development of real-time PCR array for simultaneous detection of eight human blood-borne viral pathogens
Azimi et al. Molecular detection and clinical characteristics of bacterial and viral main etiological agents causing respiratory tract infections in Tehran, Iran
Khan et al. Use of whole blood and dried blood spot for detection of HIV-1 nucleic acids using reverse transcription loop-mediated isothermal amplification
Galipienso et al. Cucumber vein yellowing virus isolate-specific expression of symptoms and viral RNA accumulation in susceptible and resistant cucumber cultivars
RU2697412C2 (ru) Экспресс-тест на основе ПЦР, позволяющий предсказывать чувствительность опухоли головного мозга конкретного пациента к онколитическим вирусам
Jasim et al. Correlation between both genetic polymorphism and serum level of toll-like receptor 4 with viral load and genotype of hepatitis C virus in Iraqi patients
Haegeman et al. Characterisation of the discrepancy between PCR and virus isolation in relation to classical swine fever virus detection
Balaraman et al. RT-qPCR genotyping assays for differentiating Rift Valley fever phlebovirus strains
RU2515911C1 (ru) Набор олигодезоксирибонуклеотидных праймеров и флуоресцентно-меченых зондов для идентификации рнк и дифференциации вируса парагриппа человека 1, 2, 3 и 4 типов
Park et al. One-step reverse transcription-polymerase chain reaction for Ebola and Marburg viruses
Flannery et al. Improved PCR diagnostics using up-to-date in silico validation: an F-gene RT-qPCR assay for the detection of all four lineages of peste des petits ruminants virus
Wu et al. Development of Taqman RT-nested PCR system for clinical SARS-CoV detection

Legal Events

Date Code Title Description
HC9A Changing information about inventors
QB4A Licence on use of patent

Free format text: LICENCE FORMERLY AGREED ON 20200226

Effective date: 20200226